Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541889 · ClinicalTrials.gov registry record · Phase 1
REVEAL Biomarkers of Engraftment After Alternative Donor HSCT
A Phase 1 study of Primary Graft Failure, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 4
- Study locations
NCT03541889 is a Phase 1 study of Primary Graft Failure that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 56 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT03541889, a Phase 1 study of Primary Graft Failure, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples to investigate whether the cells are growing well.
Conditions Studied
Interventions
- DRUG FLT imaging and TK1 blood measurements
Study Locations (4)
Georgia
- Emory University - Atlanta
Michigan
- University of Michigan - Ann Arbor
Ohio
- University Hospital of Cleveland UH Seidman Cancer Center - Cleveland
Oklahoma
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541889
The ClinicalTrials.gov registry entry for NCT03541889 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Graft Failure appearing as the primary indexed condition, and to 1 intervention - of which FLT imaging and TK1 blood measurements is the first listed.
NCT03541889 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT03541889 about?
NCT03541889 is a clinical study titled "REVEAL Biomarkers of Engraftment After Alternative Donor HSCT". The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples...
What is the current status of trial NCT03541889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-02-05. Estimated completion is 2027-11.
What conditions does trial NCT03541889 study?
This clinical trial studies the following conditions: Primary Graft Failure.
What interventions are being tested in trial NCT03541889?
The interventions under investigation include: FLT imaging and TK1 blood measurements (DRUG).
Who is sponsoring clinical trial NCT03541889?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03541889 being conducted?
This trial has 4 study locations across Georgia, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Graft Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.